Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
15,733
datasets available to search
ShareScore release 0.9.0
Dataset results
15,733 results for “article”
Dataset related to article "Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients' selection"
<p>This record contains raw data related to article "Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients' selection"</p> <p> </p> <p>Abstract: Oligoprogression is defined as limited metastatic clone resistant to on-going systemic treatment that grows in a background of stable or responding systemic disease. Aim of the present study was to analyze oligoprogressive prostate cancer (PC) patients treated with stereotactic body radiation therapy (SBRT) during systemic treatment to identify predictive factors and improve patients' selection. We included PC patients treated with SBRT on a maximum of 3 sites of oligoprogression during systemic therapy. Endpoints were freedom from polymetastatic progression (FPP), local control (LC), distant progression free survival (DPFS), overall survival (OS), and next systemic therapy free survival (NEST-FS). Fifty-three patients were treated on 85 oligoprogressive metastases. Lymph nodes were the most common sites (56.47%), followed by bone (39.29%). Median follow-up was 24.9 months. Rates of FPP at 1- and 2-year were 80.1% and 68.9%, respectively. Median time to polymetastatic progression was 33.7 months. Disease free interval (p = 0.004), site of metastases (p = 0.011), and type of systemic therapy (p = 0.003) were significant for FPP. Switch or intensification of systemic therapy after SBRT was observed in 29 (54.72%) patients with a median NEST-FS of 15.2 months. LC at 1- and 2-year was 94.0% and 92.0%, with PSA doubling time resulted to be significantly associated (p = 0.047). Median DPFS was 8.93 months and median OS was 50.6 months. In conclusion, we confirmed the efficacy of SBRT for oligoprogression from PC, with the potential to prolong the on-going systemic therapy and interrupt the metastatic cascade.</p>
Dataset related to article "Locally Advanced Non-Small Cell Lung Cancer: Clinical Outcome, Toxicity and Predictive Factors in Patients Treated with Hypofractionated Sequential or Exclusive Radiotherapy "
<p>This record contains raw data related to article “Locally Advanced Non-Small Cell Lung Cancer: Clinical Outcome, Toxicity and Predictive Factors in Patients Treated with Hypofractionated Sequential or Exclusive Radiotherapy"</p> <p>Abstract:</p> <p><strong>Background: </strong> This study evaluated the outcome, toxicity and predictive factors in patients unfit for concurrent chemo-radiotherapy (CT-RT) treated with hypofractionated sequential CT-RT or exclusive radiotherapy (RT) for locally advanced non-small cell lung cancer (LA-NSCLC).</p> <p><strong>Methods: </strong> We included patients affected by LA-NSCLC (stage IIA-IVA) treated with a total dose of 50-60 Gy in 20 fractions. The primary outcomes were local control (LC), distant metastasis-free survival (DMFS), progression-free survival (PFS) and overall survival (OS). Univariate analysis was used to correlate outcomes with prognostic factors.</p> <p><strong>Results: </strong> Between 2011 and 2019, 210 patients were treated, 113 (53.8%) with sequential CT-RT and 97 (46.2%) with exclusive RT. After a median follow-up of 15.3 months, 74 patients (35.2%) had a local progression and 133 (63.3%) had a distant progression. The one-, two- and five-year LC were 73.6%, 55.3% and 47.9%, respectively. At the time of analysis, 167 patients (79.5%) died. The one-, two- and five-year OS were 64.7%, 36% and 20%, respectively. PTV volume correlated with PFS (<em>p</em> = 0.001) and LC (<em>p</em> = 0.005). Acute and late toxicity occurred in 82% and 26% of patients.</p> <p><strong>Conclusions: </strong> Albeit with the known limitations of a retrospective and heterogeneous study, our work shows that hypofractionated sequential CT-RT or exclusive RT offer a good local control and toxicity profile and a promising survival rate in LA-NSCLC patients unfit for the concurrent CT-RT scheme.</p>
Dataset related to article "An individualized algorithm to predict mortality in COVID-19 pneumonia: a machine learning based study "
<p>This record contains raw data related to article “An individualized algorithm to predict mortality in COVID-19 pneumonia: a machine learning based study"</p> <p>Abstract:</p> <p><strong>Introduction: </strong> Identifying SARS-CoV-2 patients at higher risk of mortality is crucial in the management of a pandemic. Artificial intelligence techniques allow one to analyze large amounts of data to find hidden patterns. We aimed to develop and validate a mortality score at admission for COVID-19 based on high-level machine learning.</p> <p><strong>Material and methods: </strong> We conducted a retrospective cohort study on hospitalized adult COVID-19 patients between March and December 2020. The primary outcome was in-hospital mortality. A machine learning approach based on vital parameters, laboratory values and demographic features was applied to develop different models. Then, a feature importance analysis was performed to reduce the number of variables included in the model, to develop a risk score with good overall performance, that was finally evaluated in terms of discrimination and calibration capabilities. All results underwent cross-validation.</p> <p><strong>Results: </strong> 1,135 consecutive patients (median age 70 years, 64% male) were enrolled, 48 patients were excluded, and the cohort was randomly divided into training (760) and test (327) groups. During hospitalization, 251 (22%) patients died. After feature selection, the best performing classifier was random forest (AUC 0.88 ±0.03). Based on the relative importance of each variable, a pragmatic score was developed, showing good performances (AUC 0.85 ±0.025), and three levels were defined that correlated well with in-hospital mortality.</p> <p><strong>Conclusions: </strong> Machine learning techniques were applied in order to develop an accurate in-hospital mortality risk score for COVID-19 based on ten variables. The application of the proposed score has utility in clinical settings to guide the management and prognostication of COVID-19 patients.</p>
Dataset related to article: Distinct neural signatures of pulvinar in C9orf72 amyotrophic lateral sclerosis mutation carriers and noncarriers
<table> <tbody> <tr> <td> <p><span>The database includes clinical and MRI morphological data from a sample of 19 ALS patients carrying the C9orf72 mutation (ALSC9+), 19 non-mutation-carriers ALS patients (ALSC9-), and 19 ALS mimics (ALSmimics). The reported data consist of:<span> </span>demographic data (i.e., Age and Sex assigned at birth), clinical data (i.e., Bulbar/spinal onset, ALSFRS, Survival, disease duration, and King's Staging System scores), and volumetric information on the pulvinar subniclei (mm^3 and percentage of intracranial volume).</span></p> </td> </tr> </tbody> </table>
Dataset related to article: Resting-state fMRI functional connectome of C9orf72 mutation status
<p><span>The database includes clinical and connectome data from a sample of ALS patients carrying the C9orf72 mutation (ALSC9+), non-mutation-carriers ALS patients (ALSC9-), and ALS mimics (ALSmimics). The reported data consist of:<span> </span>demographic data (i.e., Age and Sex assigned at birth), clinical data (i.e., Bulbar/spinal onset, ALSFRS, Survival, disease duration, and King's Staging System scores), and connectome results.</span><span></span></p>
Dataset related to article: Involvement of the ipsilateral-to-the-pain anterior-superior hypothalamic subunit in chronic cluster headache
<p><strong><span>the database includes clinical data and volumes (mm^3) of hypothalamus nuclei in cluster headache patients and healthy controls</span></strong></p>
Dataset of the article "The social dimension of equine welfare: how social contact positively influences the emotional state of stalled horses".
<p>Here are the data used in the analyses of the manuscript "The social dimension of equine welfare: how social contact positively influences the emotional state of stalled horses".<br>Experiment 1: Observations in the individual stall<br>Experiment 2: Observations during horse grooming<br>Experiment 3: Judgement bias test</p> <p> </p> <p>7/6/24: Update of abbreviations used in the files</p>
Dataset related to the article "UPVnet: A Neural Network for Accurate First-Arrival Picking in Ultrasonic Pulse Velocity Testing of Rock Samples"
<p>The compressed folder contains ultrasonic pulse velocity testing data for 172 P- and S-waves of 7 types of rocks mentioned in the article, as well as demonstration code for UPVnet.</p> <h2>Note:</h2> <ol> <li>Data augmentation generated 4500 training and 500 validation waveform datasets, stored in the .npz files in the "data" folder. In "UPVnet.ipynb", if "data_augmentation=True", data augmentation is reapplied; otherwise, the ".npz" files in the data folder are directly accessed.</li> <li>In UPVnet.ipynb, when "train_mode=True", the model is retrained. Otherwise, the model parameters are directly loaded from the ".pt" file in the "data" folder.</li> <li>All ultrasonic waveform data are saved in the "datasets" folder, named according to the format "(sample number)_(transducer type)_(measurement distance)_(experiment number)". "Calibration" indicates the calibration of the transducers.</li> </ol>
Dataset related to the article "Self-Care and Quality of Life in Patients with Chronic Cardiovascular Diseases: the Role of Anxiety, Depression and Perceived Distress"
<p>This record contains raw data related to the article "Self-Care and Quality of Life in Patients with Chronic Cardiovascular Diseases: the Role of Anxiety, Depression and Perceived Distress".</p> <p>ABSTRACT:</p> <p><strong>Aim: </strong>To explore the relationship between self-care, psychological status, and quality of life in patients with chronic cardiovascular diseases.</p> <p><strong>Background:</strong> Psychological disorders are frequent among patients with chronic cardiovascular diseases, who also need to perform self-care to manage their condition. Both psychological status and self-care seem to affect the quality of life, but the relationship between these three elements is not completely understood.</p> <p><strong>Methods: </strong>397 patients with chronic cardiovascular disease were enrolled. All participants completed a self-administered test battery comprising GAD-7 (symptoms of anxiety), PHQ-9 (symptoms of depression), PSS (perceived distress), EQ5D (quality of life), and SCCII (self-care). Paths analysis was conducted.</p> <p><strong>Results: </strong>In people with chronic cardiovascular diseases, self-care and quality of life are indirectly linked via perceived distress as the mediating factor.</p> <p><strong>Conclusions: </strong>To our knowledge, this is the first study to assess the mediating role of psyhological well-being in the relationship between self-care and quality of life in patients with chronic cardiovascular diseases. Findings indicate that, in this population, self-care affects quality of life with the moderating role of perceived distress, highlighting the importance of enhancing the cooperation between nurses and psychologists in order to alleviate distress and improve quality of life in these patients.</p> <p><span><strong>THIS DATASET IS NOT PUBLIC. IS AVAILABLE UPON REASONABLE REQUEST TO THE CORRESPONDING AUTHOR</strong></span></p>
Dataset and data reproduction scripts for the article: "Constraining Earth's core composition from inner core nucleation".
<p>This dataset includes the data used in the manuscript "Constraining Earth's core composition from inner core nucleation".</p> <p>This comes in three types:</p> <p> - The fitting data and outputs to produce the embedded atom model of this work.</p> <p> - The statistics of solid nuclei observed in simulations of supercooled liquid iron at 360 GPa at a range of temperatures and carbon concentrations.</p> <p> - Melting points obtained from two-phase coexistence calculations of the same systems.</p> <p>Also included are the scripts used to generate this data. These scripts were originally run on the Archer2 HPC system.</p> <p>All data and code belong to the author, Alfred Wilson. Please request permission from the author prior to use.</p>
Dataset related to article "Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment"
<p>This record contains raw data related to article "Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment"</p> <p>ABSTRACT:</p> <p>BACKGROUND: The incidence of glioblastoma among elderly patients is constantly increasing. The value of radiation therapy and concurrent/adjuvant chemotherapy has been widely assessed. So far, the role of surgery has not been thoroughly investigated. The study aimed to evaluate safety and impact of several entities of surgical resection on outcome of elderly patients with newly diagnosed glioblastoma treated by a multimodal approach.</p> <p>METHODS:</p> <p>Patients ≥ 65 years, underwent surgery were included. The extent of surgical resection (EOR) was defined as complete resection (CR = 100%), gross total resection (GTR = 90-99%), sub-total resection (STR = 78-90%), partial resection (PR = 30-78%), and biopsy. After surgery, all patients received adjuvant radiotherapy (60/2 Gy fraction) with concomitant/adjuvant temozolomide chemotherapy.</p> <p>RESULTS:</p> <p>From March 2004 to December 2015, 178 elderly with a median age of 71 years (range 65-83 years) were treated. CR was obtained in 8 (4.5%), GTR in 63 (35.4%), STR in 46 (25.8%), PR in 16 (9.0%), and biopsy in 45 (25.3%). RT was started in all patients, concurrent/adjuvant CHT in 149 (83.7%) and 132 (74.2%). The median follow-up time was 12.2 months (range 0.4-50.4 months). The median, 1- and 2-year progression-free survival was 8.9 months (95%CI 7.8-100 months), 32.0 ± 3.5%, and 12.9 ± 2.6%. The median, 1- and 2-year overall survival were 12.2 (95%CI 11.3-13.1 months), 51.1 ± 3.7%, and 16.3 ± 2.9%. Tumor location, extent of resection, and neurological status after surgery statistically affected survival (p ≪ 0.01).</p> <p>CONCLUSION:</p> <p>Maximal surgical resection is safe and feasible in elderly patients with influence on survival. A preoperative evaluation has to be carried out.</p>
Dataset related to article "Phenotypic and molecular changes in nodule-in-nodule hepatocellular carcinoma with pathogenetic implications"
<p>This record contains raw data related to article "Phenotypic and molecular changes in nodule-in-nodule hepatocellular carcinoma with pathogenetic implications"</p> <p>AIMS:</p> <p>Nodule-in-nodule (N/N) hepatocellular carcinoma (HCC) is a convincing proof of multistep hepatocarcinogenesis. In this lesion, an inner HCC develops within an outer, more differentiated, tumour, which can be rapidly taken over by the former so that N/N HCC is rarely detected.</p> <p>METHODS AND RESULTS:</p> <p>Ten resected N/N HCCs arising in cirrhotic background and characterized: (i) as outer lesions by early (n = 3) and G1 (n = 7) HCC; (ii) as inner lesions by G1 (n = 3) and G2 (n = 7) HCC. The largest/smallest diameters of outer and inner nodules were, respectively, 20/6 mm and 16/4 mm. We investigated vascular (CD34 and endocan), hepatocellular VEGF, GS, GPC3, HSP70 and CHC) and molecular (TERT promoter and β-catenin) changes taking place from the outer neoplastic compartment to the inner neoplastic compartment (INC). A diffuse pattern of CD34+ capillarized vessels and focal endocan immunoreactivity were major distinctive features acquired in the INC; VEGF immunoreactivity was inversely related to CD34 staining. A gain in the number of cells immunoreactive for GPC3, HSP70, and CHC, but not of GS-immunoreactive cells, also occurred in the INC. TERT promoter mutations were seen in half of the cases in both compartments, whereas β-catenin mutations were more rarely detectable.</p> <p>CONCLUSIONS:</p> <p>Major phenotypic changes take place in the INC of N/N HCC. TERT promoter mutations take place frequently and very early, and, in contrast to β-catenin mutations, do not appear to be acquired during N/N growth. These findings suggest that inner nodules represent a step further along the pathway of tumour progression, in contrast to earlier, simply initiated, lesions, and that complete neovascularisation predicts a change in HCC biology.</p>
Dataset related to article "Hypofractionation with simultaneous boost in breast cancer patients receiving adjuvant chemotherapy A prospective evaluation of a case series and review of the literature"
<p>This record contains raw data related to article "Hypofractionation with simultaneous boost in breast cancer patients receiving adjuvant chemotherapy A prospective evaluation of a case series and review of the literature"</p> <p>To evaluate acute toxicity and cosmetic outcomes of hypofractionated simultaneous integrated boost (SIB) as adjuvant treatment after breast-conserving surgery and adjuvant chemotherapy and to review the association of chemotherapy and short fractionation with boost.</p> <p>MATERIALS AND METHODS:</p> <p>Patients presenting early-stage breast cancer were enrolled in a phase II trial. All patients received VMAT-SIB technique to the whole breast and tumor bed in 15 fractions, for a total dose of 40.5 and 48 Gy. Acute and late skin toxicities and breast pain were recorded. Cosmetic outcomes were also assessed as excellent/good or fair/poor.</p> <p>RESULTS:</p> <p>Between August 2010 and December 2015, 787 consecutive patients were treated and had at least 2 year follow-up. A subset of 175 patients underwent adjuvant chemotherapy (median age of 55 years) and was analysed. The median follow up was 39 months (range 24-80). At the end of RT treatment, skin toxicity was G1 in 51.1% of patients, G2 in 9.7%. At 2 years of follow up, it was G1 in 13.5% of patients, no cases ≥ G2; cosmetic outcome was excellent in 63.5% and good in 36.5% of the patients. No significant difference compared to the patients without systemic therapy was observed.</p> <p>CONCLUSION:</p> <p>Hypofractionated VMAT-SIB in patients who had undergone adjuvant systemic therapy was safe and well tolerated in terms of acute and early late settings and cosmesis. Our data confirmed the results of other studies published on the association of hypofractionation and chemotherapy or concomitant boost.</p> <p> </p> <p> </p> <p> </p> <p> </p>
Dataset related to article "Long-Term Follow-Up of Patients with Metastatic Epidural Spinal Cord Compression from Solid Tumors Submitted for Surgery Followed by Radiation Therapy"
<p>This record contains raw data related to article "Long-Term Follow-Up of Patients with Metastatic Epidural Spinal Cord Compression from Solid Tumors Submitted for Surgery Followed by Radiation Therapy"</p> <p>OBJECTIVE:</p> <p>To evaluate the outcome of patients with epidural spinal cord compression from different solid tumors treated with a combined approach, surgery plus radiotherapy (RT), with a follow-up longer than 10 years.</p> <p>METHODS:</p> <p>Ninety-seven patients treated between 2002 and 2009 were included. Surgical treatment was performed in patients with good performance status, limited metastatic disease, life expectancy longer than 3 months, and progressive neurologic deficit and/or intractable pain. RT was performed delivering a median total dose of 30 Gy in 10 fractions. Clinical outcome was evaluated using the modified visual analog scale for pain, the Frankel scale for neurologic deficit, and magnetic resonance imaging before treatment, after treatment, and every 3 months thereafter.</p> <p>RESULTS:</p> <p>Palliative decompression was performed in 27% of patients, tumor curettage (debulking) was performed in 51%, and total vertebrectomy was performed in 22%, followed by RT in 78% of cases. Pain remission was obtained in 98% of patients, and recovery of neurologic function was obtained in 51%. The median follow-up time was 135 months (range, 96-209 months). The 5- and 10-year local control rates were 82.8% and 82.8%, respectively. The median and 5- and 10-year progression-free survival rates were 12 months, 16.9%, and 11.3%, respectively; the median and 5- and 10-year overall survival rates were 18 months, 21.3%, and 12%, respectively. On univariate and multivariate analysis, factors recorded as conditioning survival were the performance status and the presence of other metastases at the time of vertebral treatment (P < 0.01).</p> <p>CONCLUSIONS:</p> <p>Our update confirmed that surgery plus RT is a safe and feasible treatment with limited morbidity. In selected patients with favorable prognostic factors, the combined treatment may significantly impact on survival.</p>
Dataset related to article "Evaluation of target dose inhomogeneity in breast cancer treatment due to tissue elemental differences"
<p>This record contains raw data related to article "Evaluation of target dose inhomogeneity in breast cancer treatment due to tissue elemental differences"</p> <p>BACKGROUND:</p> <p>Monte Carlo simulations were run to estimate the dose variations generated by thedifference arising from the chemical composition of the tissues.</p> <p>METHODS:</p> <p>CT datasets of five breast cancer patients were selected. Mammary gland was delineated as clinical target volume CTV, as well as CTV_lob and CTV_fat, being the lobular and fat fractions of the entire mammary gland. Patients were planned for volumetric modulated arc therapy technique, optimized in the Varian Eclipse treatment planning system. CT, structures and plans were imported in PRIMO, based on Monte Carlo code Penelope, to run three simulations: AdiMus, where the adipose and muscle tissues were automatically assigned to fat and lobular fractions of the breast; Adi and Mus, where adipose and muscle, respectively were assigned to the whole mammary gland. The specific tissue density was kept identical from the CT dataset. Differences in mean doses in the CTV_lob and CTV_fat structures were evaluated for the different tissue assignments. Differences generated by the tissue composition and estimated by Acuros dose calculations in Eclipse were also analysed.</p> <p>RESULTS:</p> <p>From Monte Carlo simulations, the dose in the lobular fraction of the breast, when adipose tissue is assigned in place of muscle, is overestimated by 1.25 ± 0.45%; the dose in the fat fraction of the breast with muscle tissue assignment is underestimated by 1.14 ± 0.51%. Acuros showed an overestimation of 0.98 ± 0.06% and an underestimation of 0.21 ± 0.14% in the lobular and fat portions, respectively. Reason of this dissimilarity resides in the fact that the two calculations, Monte Carlo and Acuros, differently manage the range of CT numbers and the material assignments, having Acuros an overlapping range, where two tissues are both present in defined proportions.</p> <p>CONCLUSION:</p> <p>Although not clinically significant, the dose deposition difference in the lobular and connective fat fraction of the breast tissue lead to an improved knowledge of the possible dose distribution and homogeneity in the breast radiation treatment</p>
This record contains raw data related to article: "Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study"
<p>This record contains raw data related to article "Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study"</p> <p>Comorbidity has a detrimental effect on cancer survival, however, it is difficult to disentangle its direct effect from its influence on treatment choice. In this study we assessed the effect of comorbidity on survival in patients who received standard treatment for resected stage II and III colorectal cancer (CRC).</p> <p>PATIENTS AND METHODS:</p> <p>In total, 230 CRC patients, 68 rectal (29.6%) and 162 colon cancer (70.4%) treated with surgical resection and neoadjuvant/adjuvant chemotherapy from December 2002 to December 2009 at Humanitas Cancer Center were retrospectively reviewed. The key independent variable was the Charlson Comorbidity Index (CCI) score, measured as a continuous variable. The differences between groups for categorical data were tested using the χ<sup>2</sup> test. Actuarial survival curves were generated using the Kaplan-Meier method.</p> <p>RESULTS:</p> <p>Median follow-up was 113 (range, 8.2-145.0) months. Median age was 63 (range, 37-78) years. In univariate analysis CCI score was significantly associated with poorer disease-free survival (hazard ratio [HR], 1.65; 95% confidence interval [CI], 1.52-1.80; P < .001), and overall survival (OS; HR, 1.55; 95% CI, 1.41-1.71; P < .001). Factors associated with poorer outcome also included (stage III vs. stage II, P < .029) and age (age >70 vs. ≤70 years, P < .001). After adjusting for these factors, a significant negative prognostic role of CCI score was still observed (adjusted HR for OS, 1.59; 95% CI, 1.43-1.76; P < .001).</p> <p>CONCLUSION:</p> <p>Among CRC patients who underwent surgical resection and chemotherapy, a higher CCI score was associated with poorer outcome and might predict long-term survival.</p>
Dataset related to article "Liver metastases from colorectal cancer: propensity score-based comparison of stereotactic body radiation therapy vs. microwave ablation"
<p>This record contains raw data related to article "Liver metastases from colorectal cancer: propensity score-based comparison of stereotactic body radiation therapy vs. microwave ablation"</p> <p>PURPOSE:</p> <p>The study aim was to compare the disease control in two groups of patients affected by liver metastases from CRC treated with microwave ablation (MWA) or stereotactic body radiation therapy (SBRT).</p> <p>METHODS:</p> <p>We extracted data of patients treated between 2009 and 2016. Inclusion criteria were: (1) maximum diameter of the liver lesions less than 4 cm; (2) no more than three liver lesions; (3) no evidence of progressive or untreated gross disease outside the liver; (4) adequate liver function; (5) no concurrent chemotherapy; (6) minimum age of 18. Tumour response was classified according to EORTC-RECIST criteria. Aim of the present study was to evaluate freedom from local progression (FFLP). To reduce indication bias, an inverse probability of treatment weighting was used to estimate treatment effect.</p> <p>RESULTS:</p> <p>A total of 135 patients with 214 lesions were included in the analysis. Median follow-up time was 24.5 months (range 2.4-95.8). The 1-year freedom from local progression (FFLP) was 88% (95%CI 80-92). In the SBRT group, FFLP was statistically longer than MWA group (p = 0.0214); the 1-year FFLP was 91% (95% CI 81-95) in SBRT group and 84% (95% CI 0.72-0.91) in MWA group. Patients treated with SBRT showed a reduce risk of local relapse compared to MWA (adjusted HR 0.31; 95%CI 0.13-0.70, p = 0.005). As expected, analogous result obtained in the inverse probability weighting analysis (HR 0.38; 95%CI 0.18-0.80; p = 0.011).</p> <p>CONCLUSION:</p> <p>In conclusion, there seems to be an advantage of SBRT compared to MWA in treating CRC liver metastases, particularly for lesions bigger than 30 mm.</p>
Dataset related to article: "68Ga-PSMA Positron Emission Tomography/Computerized Tomography for Primary Diagnosis of Prostate Cancer in Men with Contraindications to or Negative Multiparametric Magnetic Resonance Imaging: A Prospective Observational Study"
<p>This record contains raw data related to article 68Ga-PSMA Positron Emission Tomography/Computerized Tomography for Primary Diagnosis of Prostate Cancer in Men with Contraindications to or Negative Multiparametric Magnetic Resonance Imaging: A Prospective Observational Study</p> <p>PURPOSE:</p> <p><sup>68</sup>Ga labeled prostate specific membrane antigen positron emission tomography/computerized tomography may represent the most promising imaging modality to identify and risk stratify prostate cancer in patients with contraindications to or negative multiparametric magnetic resonance imaging.</p> <p>MATERIALS AND METHODS:</p> <p>In this prospective observational study we analyzed <sup>68</sup>Ga labeled prostate specific membrane antigen positron emission tomography/computerized tomography in a select group of patients with persistently elevated prostate specific antigen and/or Prostate Health Index suspicious for prostate cancer, negative digital rectal examination and at least 1 negative biopsy. The cohort comprised men with equivocal multiparametric magnetic resonance imaging (Prostate Imaging-Reporting and Data System, version 2 score of 2 or less), or an absolute or relative contraindication to multiparametric magnetic resonance imaging. Sensitivity, specificity and CIs were calculated compared to histopathology findings. ROC analysis was applied to determine the optimal cutoff values of <sup>68</sup>Ga labeled prostate specific membrane antigen uptake to identify clinically significant prostate cancer (Gleason score 7 or greater).</p> <p>RESULTS:</p> <p>A total of 45 patients with a median age of 64 years were referred for <sup>68</sup>Ga labeled prostate specific membrane antigen positron emission tomography/computerized tomography between January and August 2017. The 25 patients (55.5%) considered to have positive positron emission tomography results underwent software assisted fusion biopsy. We determined the uptake values of regions of interest, including a median maximum standardized uptake value of 5.34 (range 2.25 to 30.41) and a maximum-to-background standardized uptake value ratio of 1.99 (range 1.06 to 14.42). Mean and median uptake values on <sup>68</sup>Ga labeled prostate specific membrane antigen positron emission tomography/computerized tomography (ie the maximum standardized uptake value or the maximum-to-background standardized uptake value ratio) were significantly higher for Gleason score 7 lesions than for Gleason score 6 or benign lesions (p <0.001). On ROC analysis a maximum standardized uptake value of 5.4 and a maximum-to-background standardized uptake value ratio of 2 discriminated clinically relevant prostate cancer with 100% overall sensitivity in each case, and 76% and 88% specificity, respectively.</p> <p>CONCLUSIONS:</p> <p>Our findings support the use of <sup>68</sup>Ga labeled prostate specific membrane antigen positron emission tomography/computerized tomography for primary detection of prostate cancer in a specific subset of men.</p>
Dataset related to article "Prognostic Impact of Intratumoral Heterogeneity Based on Fractal Geometry Analysis in Operated NSCLC Patients"
<p>This record contains raw data related to article "Prognostic Impact of Intratumoral Heterogeneity Based on Fractal Geometry Analysis in Operated NSCLC Patients"</p> <p>PURPOSE:</p> <p>To determine the heterogeneity of glucose uptake applying fractal analysis on positron emission tomography/computed tomography (PET/CT) with 2-deoxy-2-[<sup>18</sup>F]fluoro-D-glucose ([<sup>18</sup>F]FDG) images in patients with non-small cell lung carcinoma (NSCLC) before surgery, and to assess whether this heterogeneity was associated with disease-free survival (DFS).</p> <p>PROCEDURES:</p> <p>[<sup>18</sup>F]FDG PET/CT scans of 113 patients' prior surgery were retrospectively revised. PET DICOM images were analyzed for fractal geometry using a ad hoc software to automatically determine the following indexes: (a) mean intensity value (MIV), (b) standard deviation (SD), (c) relative dispersion (RD), (d) three-dimensional (3D) histogram of the fractal dimension (3D HIST FR DIM), and (e) fractal dimension in 3D (3D-FD). All the fractal indexes were subsequently compared with metabolic parameters and disease-free survival (DFS).</p> <p>RESULTS:</p> <p>We found a significant correlation between 3D-FD and SUVmax, SUVmean, MTV, and TLG. Additionally, positive correlations between MIV, SD, and all metabolic parameters were also detected. Patients with high 3D-FD tumor (≥ 1.62) showed significantly higher values of SUVmax, SUVmean, MTV, and TLG than those with lower 3D-FD. In univariate analysis, median 3D-FD and median TLG were significantly associated with DFS (p = 0.04 and p = 0.03, respectively). These findings were confirmed on log-rank test. On multivariate analysis, among age, stage disease, histotype, 3D-FD, and metabolic parameters, only 3D-FD was identified as independent prognostic factor for DFS (p = 0.032; HR 0.418, 95 % CI 0.189-0.926). 3D-FD was different between adenocarcinoma and squamous cell carcinoma (1.60 versus 1.88, p = 0.014), and 3D-FD value was found higher in advanced stage disease.</p> <p>CONCLUSIONS:</p> <p>Metabolic heterogeneity determined applying fractal principles on PET images can be considered as a novel imaging biomarker for survival in patients with NSCLC.</p>
Dataset related to article "18F-FDG PET/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors "
<p>This record contains raw data related to article 18F-FDG PET/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors</p> <p>Our aim was to evaluate Hodgkin Lymphoma (HL) response to checkpoint inhibitors with <sup>18</sup>F-FDG PET/CT. Forty three refractory or relapsed HL patients were investigated before immunotherapy, 8 weeks and 17 weeks after administration of either nivolumab or pembrolizumab. The median follow-up was 19 months. Best clinical response was complete response (CR) in 26 patients, partial response (PR) in 5 patients, stable disease (SD) in 8 patients, and progression disease (PD) in 4 patients. At the early assessment, Deauville Score (DS) resulted significantly different in responder group compared to nonresponders. SUVmax was significantly lower in responders, while there was no relevant modification in the tumor burden. At interim evaluation, DS well differentiated responder group. A significant decrease in glucose metabolism and tumor burden parameters was observed in responder patients, who presented with a longer progression-free survival then nonresponders. <sup>18</sup>F-FDG PET/CT provides a reliable indication of treatment response under checkpoints inhibitors, even at an early assessment.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.